Switching from aflibercept to ranibizumab biosimilars maintains stability in nAMD treatment, offering a cost-effective ...
Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 ...
Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...
The companies have proposed a strategic partnership in which Ikarovec will continue to develop its IKAR-003 gene therapy using VectorBuilder's tech.
A custom 30 G needle with a closed tip and side port shows equivalent performance to standard needles for anti-VEGF delivery.
Novel capsid technology to enable convenient delivery in the doctor's office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening disease Ikarovec Ltd, which is devel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback